Bill SponsorBILLSPONSOR
Bill Sponsor
Politicians
Bills
House Bill 4553
116th Congress(2019-2020)
Adding Epidemic Diseases to the FDA Priority Review Voucher Program Act
Introduced
Introduced
Introduced in House on Sep 27, 2019
Overview
Text
Introduced in House 
Sep 27, 2019
Not Scanned for Linkage
About Linkage
Multiple bills can contain the same text. This could be an identical bill in the opposite chamber or a smaller bill with a section embedded in a larger bill.
Bill Sponsor regularly scans bill texts to find sections that are contained in other bill texts. When a matching section is found, the bills containing that section can be viewed by clicking "View Bills" within the bill text section.
Bill Sponsor is currently only finding exact word-for-word section matches. In a future release, partial matches will be included.
Introduced in House(Sep 27, 2019)
Sep 27, 2019
Not Scanned for Linkage
About Linkage
Multiple bills can contain the same text. This could be an identical bill in the opposite chamber or a smaller bill with a section embedded in a larger bill.
Bill Sponsor regularly scans bill texts to find sections that are contained in other bill texts. When a matching section is found, the bills containing that section can be viewed by clicking "View Bills" within the bill text section.
Bill Sponsor is currently only finding exact word-for-word section matches. In a future release, partial matches will be included.
Jump To
H. R. 4553 (Introduced-in-House)


116th CONGRESS
1st Session
H. R. 4553


To expand the tropical disease product priority review voucher program to encourage treatments for the Middle East respiratory syndrome, Nipah, and Rift Valley fever.

IN THE HOUSE OF REPRESENTATIVES

September 27, 2019

Mr. Brendan F. Boyle of Pennsylvania (for himself, Mr. Marshall, Mr. Veasey, and Mr. Fortenberry) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To expand the tropical disease product priority review voucher program to encourage treatments for the Middle East respiratory syndrome, Nipah, and Rift Valley fever.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. Short title.

This Act may be cited as the “Adding Epidemic Diseases to the FDA Priority Review Voucher Program Act”.

SEC. 2. Expanding tropical disease product priority review voucher program to encourage treatments for Middle East respiratory syndrome, Nipah, and Rift Valley fever.

Section 524(a)(3) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360n(a)(3)) is amended—

(1) by redesignating subparagraph (S) as subparagraph (V); and

(2) by inserting after subparagraph (R) the following:

    “(S) Middle East respiratory syndrome.

    “(T) Nipah.

    “(U) Rift Valley fever.”.